Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Charles Dinarello to Shock, Septic

This is a "connection" page, showing publications Charles Dinarello has written about Shock, Septic.

 
Connection Strength
 
 
 
1.250
 
  1. Chernow B, Dinarello CA. Introduction: surviving septic shock. Chest. 1997 Dec; 112(6 Suppl):320S.
    View in: PubMed
    Score: 0.114
  2. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997 Dec; 112(6 Suppl):321S-329S.
    View in: PubMed
    Score: 0.114
  3. Dinarello CA. Cytokines as mediators in the pathogenesis of septic shock. Curr Top Microbiol Immunol. 1996; 216:133-65.
    View in: PubMed
    Score: 0.100
  4. Dinarello CA. Blocking interleukin-1 receptors. Int J Clin Lab Res. 1994; 24(2):61-79.
    View in: PubMed
    Score: 0.087
  5. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013 Dec 15; 25(6):439-48.
    View in: PubMed
    Score: 0.086
  6. Dinarello CA, Cannon JG. Cytokine measurements in septic shock. Ann Intern Med. 1993 Oct 15; 119(8):853-4.
    View in: PubMed
    Score: 0.086
  7. Granowitz EV, Porat R, Orencole SF, Callahan MV, Lynch EA, Wolff SM, Dinarello CA. Granulocyte-macrophage colony-stimulating factor synthesis during experimental endotoxemia in humans. J Infect Dis. 1992 Nov; 166(5):1204-5.
    View in: PubMed
    Score: 0.080
  8. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis. 1991 Jun; 163(6):1177-84.
    View in: PubMed
    Score: 0.073
  9. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 01; 5(3):338-43.
    View in: PubMed
    Score: 0.071
  10. Dinarello CA, Okusawa S, Gelfand JA. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. Prog Clin Biol Res. 1989; 286:243-63.
    View in: PubMed
    Score: 0.062
  11. Ikejima T, Okusawa S, van der Meer JW, Dinarello CA. Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis. 1988 Nov; 158(5):1017-25.
    View in: PubMed
    Score: 0.061
  12. Jones-Carson J, Fantuzzi G, Siegmund B, Dinarello C, Tracey KJ, Wang H, Fang FC, Vazquez-Torres A. Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. J Infect Dis. 2005 Sep 15; 192(6):1039-46.
    View in: PubMed
    Score: 0.049
  13. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine. 2003 Jun 01; 21 Suppl 2:S24-34.
    View in: PubMed
    Score: 0.042
  14. Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, Opal SM, Glauser M, Parsons P, Fisher CJ, Repine JE. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med. 2000 Jan; 28(1):232-5.
    View in: PubMed
    Score: 0.033
  15. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016 Feb; 44(2):275-81.
    View in: PubMed
    Score: 0.025
  16. Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Netw. 1994 Nov-Dec; 5(6):517-31.
    View in: PubMed
    Score: 0.023
  17. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunol Today. 1993 Jun; 14(6):260-4.
    View in: PubMed
    Score: 0.021
  18. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Trends Pharmacol Sci. 1993 May; 14(5):155-9.
    View in: PubMed
    Score: 0.021
  19. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993 Jan 14; 328(2):106-13.
    View in: PubMed
    Score: 0.020
  20. Dinarello CA. Blocking interleukin-1 in disease. Blood Purif. 1993; 11(2):118-27.
    View in: PubMed
    Score: 0.020
  21. Dinarello CA. The role of interleukin-1 in host responses to infectious diseases. Infect Agents Dis. 1992 Oct; 1(5):227-36.
    View in: PubMed
    Score: 0.020
  22. Cannon JG, Clark BD, Wingfield P, Schmeissner U, Losberger C, Dinarello CA, Shaw AR. Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia. J Immunol. 1989 Apr 01; 142(7):2299-306.
    View in: PubMed
    Score: 0.016
  23. Dinarello CA. The biology of interleukin 1 and comparison to tumor necrosis factor. Immunol Lett. 1987 Dec; 16(3-4):227-31.
    View in: PubMed
    Score: 0.014
  24. van Deuren M, van der Ven-Jongekrijg J, Vannier E, van Dalen R, Pesman G, Bartelink AK, Dinarello CA, van der Meer JW. The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood. 1997 Aug 01; 90(3):1101-8.
    View in: PubMed
    Score: 0.007
  25. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992 May 01; 79(9):2196-200.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)